TY - JOUR
T1 - Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States
AU - Bell, Jill A.
AU - Galaznik, Aaron
AU - Farrelly, Eileen
AU - Blazer, Marlo
AU - Murty, Sharanya
AU - Ogbonnaya, Augustina
AU - Eaddy, Michael
AU - Fram, Robert J.
AU - Faller, Douglas V.
AU - Kota, Vamsi
N1 - Publisher Copyright:
© 2018 The Authors
PY - 2018/8
Y1 - 2018/8
N2 - This retrospective claims database study examined healthcare utilization (HCU) and costs associated with acute myeloid leukemia (AML) in 237 elderly patients who received chemotherapy or a stem cell transplant (SCT) following AML diagnosis. Patients with secondary AML were excluded. Over the entire follow-up period, 92.0% of patients had ≥1 inpatient admission; 85.7% had ≥1 AML-related admission, and 42.6% had ≥1 non-AML-related admission. During inpatient admissions, 39.2% of patients had ≥1 intensive care unit (ICU) admission, with 20.7% having ≥1 AML-related ICU admission, and 27.8% having ≥1 non-AML-related ICU admission. Total mean per-patient per-month (PPPM) costs over the follow-up period were $25,243 (SD: $21,909), with costs from Year 1 ($27,756 [SD: $22,121]) more than double those in Year 2 ($12,953 [SD: $26,334]) following AML diagnosis. The majority of total costs were medical ($24,512 PPPM [SD: $21,704]), which included inpatient admissions ($6548 PPPM [SD: $10,777]), other outpatient visits ($5021 PPPM [SD: $7997]), supportive care ($3640 PPPM [SD: $5589], and chemotherapy administration ($2029 PPPM [SD: $2345]). Healthcare costs of treated elderly AML patients are substantial, particularly in the first year following diagnosis. Further research is needed to understand factors contributing to high costs in various settings of care for elderly AML patients.
AB - This retrospective claims database study examined healthcare utilization (HCU) and costs associated with acute myeloid leukemia (AML) in 237 elderly patients who received chemotherapy or a stem cell transplant (SCT) following AML diagnosis. Patients with secondary AML were excluded. Over the entire follow-up period, 92.0% of patients had ≥1 inpatient admission; 85.7% had ≥1 AML-related admission, and 42.6% had ≥1 non-AML-related admission. During inpatient admissions, 39.2% of patients had ≥1 intensive care unit (ICU) admission, with 20.7% having ≥1 AML-related ICU admission, and 27.8% having ≥1 non-AML-related ICU admission. Total mean per-patient per-month (PPPM) costs over the follow-up period were $25,243 (SD: $21,909), with costs from Year 1 ($27,756 [SD: $22,121]) more than double those in Year 2 ($12,953 [SD: $26,334]) following AML diagnosis. The majority of total costs were medical ($24,512 PPPM [SD: $21,704]), which included inpatient admissions ($6548 PPPM [SD: $10,777]), other outpatient visits ($5021 PPPM [SD: $7997]), supportive care ($3640 PPPM [SD: $5589], and chemotherapy administration ($2029 PPPM [SD: $2345]). Healthcare costs of treated elderly AML patients are substantial, particularly in the first year following diagnosis. Further research is needed to understand factors contributing to high costs in various settings of care for elderly AML patients.
KW - Acute myeloid leukemia
KW - Cost
KW - Elderly
KW - Healthcare burden
KW - Healthcare utilization
UR - http://www.scopus.com/inward/record.url?scp=85048896177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048896177&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2018.06.010
DO - 10.1016/j.leukres.2018.06.010
M3 - Article
C2 - 29944984
AN - SCOPUS:85048896177
SN - 0145-2126
VL - 71
SP - 27
EP - 33
JO - Leukemia Research
JF - Leukemia Research
ER -
